U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07704658) titled 'Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors' on July 09.
Brief Summary: An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
NSCLC (Non-small Cell Lung Cancer)
Thyroid Cancer
Solid Tumor Malignancies
Advanced Malignancies
Intervention:
DRUG: Pralsetinib
Pralsetinib 400mg orally ...